Novel Challenges and Advances in Lung Cancer

Dear Colleagues,

Lung cancer remains the leading cause of cancer-related deaths worldwide. It is often diagnosed after it has reached an advanced stage, and its delayed diagnosis significantly worsens the patient’s prognosis. Even though, in recent years, we have observed significant progress in both diagnostics and therapy, the results of treatment in advanced disease are still unsatisfactory.

In this Special Issue, we welcome both original research articles and reviews. The aim is to present the most up-to-date and cutting-edge studies into the mechanisms contributing to the development and progression of lung cancer. Research areas may include, but are not limited to:

• Lung cancer diagnostics and biomarkers;
• Prognostic and predictive factors;
• Advances in currently used treatment options;
• Novel and emerging therapies.

Dr. Michał Szczyrek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• molecular biology
• chemotherapy
• immunotherapy
• molecularly targeted therapies
• prognostic and predictive factors